Theriva Biologics TOVX
NYSE TOVX
$0.23 +0.01 (+2.40%)
As of: Oct 1, 2026 · 3:56 PM EDT

Theriva Biologics (TOVX) EBITDA Margin (2010 - 2026)

Updated

Theriva Biologics (TOVX) recorded EBITDA Margin of -701.00% in Q1 2026.

Analysis

Theriva Biologics (TOVX) EBITDA Margin (2010 - 2026) Analysis & Trends

For FY2010, Theriva Biologics reported EBITDA Margin of -28.19%.

  • The Q1 2026 figure is the highest quarterly EBITDA Margin since Q3 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Theriva Biologics 10.56 Mn 10.56 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -701.00%
Sep 30, 2011 -308.85%
Jun 30, 2011 -252.70%
Sep 30, 2010 -221.50%
API Access

Theriva Biologics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TOVX&period=max&api_key=YOUR_API_KEY